Drugs / AVI-014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00497809 | Aug 2007 → Jul 2008 | breast cancer, neutropenia | AviGenics | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03118492 Background | May 2017 → Apr 2027 expected | myelofibrosis | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVI 014 | “The overall purpose of this study is to assess the dose response, efficacy, and safety of three different dose levels of AVI 014 (granulocyte colony-stimulating factor [G-CSF])...” NCT00497809 ↗ |
| Modality | Protein / enzyme biologic | “Glycosylated Recombinant Human G-CSF AVI-014” NCT03118492 ↗ |
| Route | Intravenous | “Given IV” NCT03118492 ↗ |